Over 200 Metastatic Breast Patients To Converge On Washington D.C. For Launch Of Metastatic Breast Cancer Advocacy Agenda
Patients will join with METAvivor to launch an ambitious advocacy agenda to help increase funding for research and to advocate for access to care for people with Stage IV, metastatic cancer
ANNAPOLIS, Md. - Oct. 8, 2018 - PRLog -- METAvivor Research and Support Inc., a non-profit organization dedicated to funding research for Stage IV, metastatic breast cancer, announced the launch of its Stage IV Stampede campaign. The campaign will commence with a day of action on October 10, 2018 in Washington, DC that will include a march, a Die-In (hosted by partner MET-UP), a panel discussion and visits with Congressional offices. The day of action is part of a series of events in the run-up to metastatic breast cancer awareness day on October 13. The Stage IV Stampede is a grassroots advocacy and awareness effort to request increased funding for research on Stage IV metastatic cancer, to improve access to life-extending treatments and to encourage congressional leaders to expedite health benefits for those with Stage IV metastatic disease and other terminal illnesses.
Metastatic breast cancer (also known as Stage IV or advanced stage cancer) is the spread of breast cancer to non-adjacent parts of the body -- most commonly to the bones, liver, lungs and/or brain. Currently, metastatic breast cancer is minimally treatable, but not survivable. Much of the current metastatic cancer research is focused on preventing metastasis rather than trying to save the lives of those who have already metastasized. Metastatic breast cancer accounts for 100% of the more than 40,000 annual deaths due to breast cancer. Metastases is not unique to breast cancer, all cancers can and do metastasize thus, approximately 600,000 Americans continue to perish each year as a result, and 90% of those individuals die from cancers that have spread.
METAvivor has partnered with a number of organizations on the campaign, including MET Up, the Male Breast Cancer Coalition, Like Neighbors and the Fraternal Order of Eagles. Corporate sponsors of the advocacy initiative include Novartis, Pfizer, Eisai, Susan G. Komen and M3 Global.
The coalition of organizations, sponsors and supporters is focused on advocacy for three main issues:
1. Expand the metastatic cancer research portfolio at the National Institutes of Health (NIH) in Fiscal Year (FY) 2018 & FY 2019 through growth in appropriations and demonstrated congressional interest in controlling and eliminating cancer that has already disseminated (metastasized)
2. Express support for the Metastatic Breast Cancer Access to Care Act to expedite disability benefits for those disabled people with terminal disease by shortening the arbitrary waiting period, for individuals with a variety of serious, debilitating, and life-threatening medical conditions face incredible hardships in supporting themselves and their families and maintaining access to appropriate medical care that they desperately need.
3. Express support for the Drug Parity Act to ensure health plans covering chemotherapy, facilitate access to all available treatment regiments.
According to METAvivor president Beth Fairchild, "As a stage IV metastatic breast cancer patient, it is important to me that we launch this day of action and critical advocacy plan for patients with stage IV, metastatic breast cancer. We have the potential to make a significant difference in the survival of many metastatic patients but we cannot do this without substantial change in how we fund research. We lose 113 people every day to metastatic breast cancer. We can only stop this by funding metastatic cancer research at a much higher level. I am so proud of all of the men and women, who are living with metastatic breast cancer that feel compelled to come to Washington D.C. to share the urgency of these issues."
METAvivor Research and Support Inc. is an Annapolis-based, 501(c)(3), volunteer-led, non-profit organization founded by metastatic breast cancer (MBC) patients in 2009. METAvivor raises awareness of MBC, provides support for people living with this disease, and offers many opportunities for others to help make a difference for the metastatic community. 100% of all donations made to METAvivor go to fund critical research that will lead to advances in treatment options, improvement of quality of life and survival for patients diagnosed with MBC.
Since 2009, METAvivor has expanded nationwide and awarded 40 research grants totaling close to $4,200,000. METAvivor has gained a rapidly growing following within the breast cancer community and has become a leader in its field. METAvivor is the only national organization with a peer-reviewed grant program aimed at exclusively funding MBC research.
Visit us at METAvivor.org, and follow us on Facebook, Twitter and Instagram.
Sonya Negley, Executive Director